Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04287387
Other study ID # APIMCAS2018001
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date March 2, 2020
Est. completion date March 2, 2021

Study information

Verified date February 2020
Source Peking Union Medical College Hospital
Contact Weigang zhao, MD
Phone +86 69151876
Email xiehezhaoweigang@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Intestinal microflora refers to the trillions of microorganisms living in our gut, which is considered as an independent endocrine organ of human body. Intestinal microbiota plays a very important role in human health. The composition of human intestinal microbiota is affected by a variety of factors, including age, living region, eating habits, nutrition, probiotics, antibiotics and so on. It is found that the imbalance of intestinal microbiota is closely related to the occurrence and development of metabolic diseases including type 2 diabetes mellitus (T2DM). There are great differences in the structure and function of intestinal microbiota between healthy people and T2DM patients, and recently changes of intestinal microbiota have been observed in pre-diabetes. In recent years, it has been found that some commonly used hypoglycemic drugs may regulate and improve the imbalance of intestinal flora of T2DM patients, including metformin, α - glucosidase inhibitor, and Glucagon-like peptide-1(GLP-1) receptor agonist, which have a positive impact on the short chain fatty acid (SCFAs) producing bacteria. However, on the one hand, subjects of those studies were mostly western population and there were just a few studies on the influence of anti-diabetic drug on human gut microbiota in Chinese population, on the other hand, the study of influence of Dipeptidyl peptidase-4(DPP-4) inhibitors, sulfonylureas, sodium-dependent glucose transporters-2(SGLT-2) inhibitors or thiazolidinediones on intestinal microbiota is rare or even absent. This study aims to explore the effect of different hypoglycemic drugs on intestinal flora and find the potential intestinal target of drug action in Chinese population.


Description:

In this study, T2DM patients who were free of anti-diabetic drugs or those have taken hypoglycemic drugs and ready to add a new drug were recruited, they were treated with metformin, α - glucosidase inhibitor, DPP-4 inhibitors, sulfonylureas, SGLT-2 inhibitors, or thiazolidinediones according to their state of illness. Faecal specimen will be collected for test of composition of gut microbiota at baseline and 4-week, 8-week,12-week after taking medication. At baseline, patients will take physical examination and blood test, every patient will complete the questionnaire under the direction of doctors to get their general information and diet habits. Physical examination and blood test will repeat at 4-week, 8-week,12-week after treatment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 180
Est. completion date March 2, 2021
Est. primary completion date March 2, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- According to the diagnostic criteria of World Health Organization (WHO) in 1999, type 2 diabetes mellitus was diagnosed clinically

- The age ranged from 18 to 65 years (including 18 and 65 years)

- Free of hypoglycemic drugs in the past 3 months; or have taken hypoglycemic drugs, and other hypoglycemic drugs need to be added at present.

- Sign written consent form voluntarily

Exclusion Criteria:

- Other types of diabetes mellitus

- At least in the last 1 month, no antibiotics or microbial agents have been used

- History of infectious diseases such as tuberculosis, viral hepatitis, HIV, and periodontal disease; history of dental disease

- Acute complications of diabetes mellitus within 6 months

- History of myocardial infarction or stroke within 6 months, or existing severe cardiovascular disease and risk

- Abnormal liver function [i.e. serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is 1.5 times higher than the upper limit of normal value];Abnormal renal function [glomerular filtration rate=60 ml/min]

- Severe hypertension that defined as systolic blood pressure =160 mmHg, diastolic blood pressure =90 mmHg with drug therapy, or hypotension (resting seat blood pressure < 90/50 mmHg)

- History of acute and chronic gastroenteritis or gastrointestinal surgery

- psychosis, alcohol dependence or history of drug abuse, lactation women, participation in other studies three months before the trial, allergic constitution or allergic to a variety of drug and those researchers think inappropriate to the research.

Study Design


Intervention

Drug:
Glucophage 500Mg Tablet
0.5g three times daily
Acarbose Tablets
50mg three times daily
Sitagliptin tablet
100mg once daily
Dapagliflozin Tablet
10mg once daily
Pioglitazone Tablets
30mg once daily
Glimepiride Tablets
2mg once daily

Locations

Country Name City State
China Peking Union Medical College Hospital Beijing Beijing

Sponsors (2)

Lead Sponsor Collaborator
Peking Union Medical College Hospital Chinese Academy of Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes from baseline to post-treatment in composition in gut microbiota analyzed by meta-genome sequencing. Baseline, Week 4, Week 8, Week 12
Primary Changes from baseline to post-treatment in composition in fasting blood glucose. Baseline, Week 4, Week 8, Week 12
Primary Changes from baseline to post-treatment in composition in level of TNF-a. Baseline, Week 4, Week 8, Week 12
Primary Changes from baseline to post-treatment in composition in fasting insulin. Baseline, Week 4, Week 8, Week 12
Primary Changes from baseline to post-treatment in blood lipid including cholesterol, triglycerides, high-density lipoprotein. Baseline, Week 4, Week 8, Week 12
Primary Changes from baseline to post-treatment in composition in 2-hour postprandial blood glucose. Baseline, Week 4, Week 8, Week 12
Primary Changes from baseline to post-treatment in composition in level of IL-6. Baseline, Week 4, Week 8, Week 12
Primary Changes from baseline to post-treatment in composition in level of IL-8. Baseline, Week 4, Week 8, Week 12
Primary Changes from baseline to post-treatment in composition in level of IL-10. Baseline, Week 4, Week 8, Week 12
Primary Changes from baseline to post-treatment in composition in level of C-reative protein. Baseline, Week 4, Week 8, Week 12
Secondary The linear relationship between gut microbiota and blood glucose and blood lipid level. Week 4, Week 8, Week 12
Secondary The linear relationship between gut microbiota and inflammation factors level. Week 4, Week 8, Week 12
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Active, not recruiting NCT02248311 - "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population N/A
Completed NCT02653300 - A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH) Phase 2
Completed NCT03655535 - Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes Phase 2
Completed NCT03256747 - Effects of Neuromuscular Electrical Stimulation on Glucose Variability in Patients With Type 2 Diabetes N/A
Completed NCT05343767 - Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus N/A
Withdrawn NCT03675074 - Neujia Anastomosis for Treatment of Obesity and Type II Diabetes N/A
Withdrawn NCT03190798 - Effects of Canagliflozin on Intravascular Volume and Hemodynamics Phase 4
Withdrawn NCT03437330 - Empagliflozin Effect on Glucose Toxicity Phase 4
Withdrawn NCT03008395 - Empowerment, Motivation and Medical Adherence (EMMA). N/A
Not yet recruiting NCT05539066 - AI Health Assistant and Type 2 Diabetes N/A
Completed NCT03682445 - Metabolic, Physical Responses To Exercise In Patients With Type 2 Diabetes Mellitus N/A
Not yet recruiting NCT03239119 - The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus Phase 3
Completed NCT03259789 - Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects Phase 3
Recruiting NCT03506230 - Financial Incentives for Low Socioeconomic Diabetic Patients N/A
Completed NCT03072407 - MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM Phase 1
Completed NCT05668442 - Feasibility of an Online Exercise Community Among Individuals With Type 2 Diabetes
Completed NCT02956044 - Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin Phase 1
Completed NCT02964572 - Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes N/A
Completed NCT02628392 - A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) N/A